An Observational Study of Patients With Dermatologic Disease
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorTarget PharmaSolutions, Inc.
About this trial
TARGET-DERM+ is an observational research study to conduct a comprehensive review of outcomes for patients with dermatologic disease (DD) and providers who treat these patients. The study includes patients managed for DD of any etiology in usual clinical practice in the United States and addresses important clinical questions regarding the management of DD by collecting and analyzing data from patients at academic medical centers and community medical practices and/or data from providers who treat them.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adult or pediatric participants managed for DD invited to participate OR a provider who treats patients with these conditions. Informed consent is required for all Engaged Cohort participants.
Adult or pediatric participants at the time of enrollment with a diagnosis of DD by ICD code or other relevant healthcare code as part of the EHR interface.
Disqualifiers
Participant withdrew consent; Failure to complete activities as required per the cohort clarification letter.
Trial population
2,000,000
Trial design
Design model
Cohort
Time perspective
Other
Treatments tested in this trial
Not listed
Trial groups
2,000,000 Participants
are grouped into 2 trial groupsGroup A: Disease Cohort
Group B: Engaged Cohort
Trial outcomes
Primary outcomes
1
To assess safety and effectiveness of DD treatments and treatments for complications of any dermatologic disease
The study will evaluate the characteristics of patients receiving various treatments, effectiveness of treatment, and medical events that develop while receiving treatment for DD
Time frame
15 years2
To characterize the natural history of disease in patients with dermatologic disease from various etiologies
A detailed analysis of available demographics (age, race, sex, country of birth, insurance status), medications, co-morbidities, and medical history from sites across the US will inform the profile for this patient population.
Time frame
15 years3
To establish learning health networks focused on quality of care for patients
Identify deficiencies and best practices in care of patients with DD. • Evaluate outcomes from targeted learning content in the management of patients with DD.
Time frame
15 yearsSecondary outcomes
1
To evaluate provider management practices in the treatment of patients with DD
Health care provider type, clinic setting, reason for initiating/not initiating/adjusting dosing of treatments, reason for discontinuing/switching treatments, and monitoring outcomes on and off treatment, will be captured as available in the provided EHR and/or through linked data.
Time frame
15 years2
To evaluate longitudinal and patient reported outcomes in DD
Longitudinal clinical outcomes and disease progression will be assessed. Self-reported patient health measures collect information directly from patients to measure physical, mental, and social health.
Time frame
15 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: